Reyataz label
Interaction Color Code
Clinical Bottom Line
Do not coadminister: Reduced levels of atazanavir
Drug 1
Drug 1 dose
300 mg daily
Drug 1 effect
Atazanavir Cmax decreased 24%, Cmin decreased 20%
Drug 2 dose
Elvitegravir 85 mg daily with cobicistat 150 mg daily
Drug 2 effect
Elvitegravir AUC increased 17%, Cmax decreased 16%, Cmin increased 83%
Clinical Effects
Potential loss of antiretroviral efficacy
Management
Use alternative agents
Import ID
840
